Endra Life Sciences Inc (NDRA) Stock Price, Quote & News

Company Profile

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 734 335 0468

Website: endrainc.com

Address:

3600 Green Court, Suite 350, Ann Arbor, United States

topstockalerts Mar. 20 at 6:01 PM

$NDRA tends to move with catalyst flow, not constant action but can trend when it gets going.

0 · Reply

BlazingStocks Mar. 20 at 5:38 PM

$NDRA - The study demonstrated the device’s robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately 30% of adults worldwide. https://finance.yahoo.com/news/endra-taeus-liver-device-demonstrates-130000684.html

0 · Reply

BlazingStocks Mar. 20 at 3:35 PM

$NDRA News February 26, 2026 ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care https://finance.yahoo.com/news/endra-taeus-liver-device-demonstrates-130000684.html

0 · Reply

BlazingStocks Mar. 19 at 7:41 PM

$NDRA - SQ Innovation also announced that it signed a Medicaid National Drug Rebate Agreement (NDRA) with CMS and that Lasix ONYU is available to 340B-eligible hospitals, medical facilities and pharmacies. https://finance.yahoo.com/news/sq-innovations-lasix-onyu-now-133000030.html

0 · Reply

NewsAndFilings Mar. 19 at 7:04 PM

Stocks Under $10 to Watch in 2026: $IBRX, $VTIX, $NDRA, $SMX — Emerging Themes Across Biotech, XR, Diagnostics, and AI Supply Chains https://thestreetreports.com/stocks-under-10-to-watch-in-2026-ibrx-vtix-ndra-smx-emerging-themes-across-biotech-xr-diagnostics-and-ai-supply-chains/

0 · Reply

BlazingStocks Mar. 19 at 2:35 PM

$NDRA News February 09, 2026 SQ Innovation's Lasix® ONYU Now Available for Order Through Major U.S. Pharmaceutical Distributors https://finance.yahoo.com/news/sq-innovations-lasix-onyu-now-133000030.html

0 · Reply

BlazingStocks Mar. 18 at 7:25 PM

$NDRA - "Our data show TAEUS tracks MRI-PDFF closely across the full SLD spectrum, including the critical 12-22% range. Additionally, at the 8% LFF threshold used for Rezdiffra™ reimbursement determination, TAEUS delivered a high PPV as well." https://finance.yahoo.com/news/endra-taeus-liver-matches-mri-130000967.html

0 · Reply

SmallCapGrowth Mar. 18 at 4:29 PM

🚨 $NDRA MRI ON HIGH ALERT 🚨💯🚀 Fresh heat — ENDRA Life Sciences' TAEUS® Liver Device just dropped HIGH-LEVEL CONSISTENCY results: ICC of 0.89, SEM of 3.3% — delivering MRI-level precision for liver fat detection right at the point of care! 🔥 This non-invasive beast is crushing it for MASLD/MASH (liver disease affecting BILLIONS globally) — matching MRI-PDFF at key trial thresholds, no radiation, cheaper/faster than MRI! ✅ Recent clinical study: rock-solid repeatability ✅ Positioning for massive pharma trials & adoption ✅ Nano ~$3.8-4M market cap at ~$3.30/share + low float = extreme volatility setup ✅ Biotech runners explode on medtech validation like this Real data catalyst in a microcap med device play — liver fat monitoring is a multi-billion unmet need!' Who's loading $NDRA before the next leg up? 👀 DYOR | NFA #NDRA #TAEUS #LiverDisease #MASLD #MASH #MedTech #BiotechStocks #PennyStocks #StockAlert @frontpagestocks

0 · Reply

BlazingStocks Mar. 18 at 3:14 PM

$NDRA News December 04, 2025 ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use https://finance.yahoo.com/news/endra-taeus-liver-matches-mri-130000967.html

0 · Reply

BlazingStocks Mar. 17 at 7:13 PM

0 · Reply

ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

Dec 4, 2025, 8:00 AM EST - 3 months ago

ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

Nov 20, 2025, 8:00 AM EST - 4 months ago

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

Nov 17, 2025, 8:00 AM EST - 4 months ago

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

Nov 13, 2025, 8:00 AM EST - 4 months ago

ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA

Oct 23, 2025, 8:00 AM EDT - 5 months ago

ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings

Oct 13, 2025, 8:00 AM EDT - 5 months ago

ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca

Aug 14, 2025, 4:05 PM EDT - 7 months ago

ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results

Jun 16, 2025, 8:00 AM EDT - 9 months ago

ENDRA's Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

May 15, 2025, 4:05 PM EDT - 11 months ago

ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

Mar 31, 2025, 8:05 AM EDT - 1 year ago

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

Mar 31, 2025, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

Nov 22, 2024, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nov 15, 2024, 9:24 AM EST - 1 year ago

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 12, 2024, 8:00 AM EST - 1 year ago

Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

Oct 22, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

Aug 30, 2024, 8:54 AM EDT - 1 year ago

Data I/O And 2 Other Stocks Under $5 Executives Are Buying

DAIO

Aug 28, 2024, 4:17 PM EDT - 1 year ago

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

Aug 22, 2024, 4:14 PM EDT - 1 year ago

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 16, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Announces Reverse Stock Split

Aug 13, 2024, 4:05 PM EDT - 1 year ago

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

Aug 13, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences Announces Leadership Changes

Aug 7, 2024, 8:00 AM EDT - 1 year ago

ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14

Jun 4, 2024, 9:21 AM EDT - 1 year ago

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

Jun 4, 2024, 9:06 AM EDT - 1 year ago

AM Best to Host Webinar on Engaging Defense Counsel Pre-Lawsuit

May 20, 2024, 8:00 AM EDT - 1 year ago

ENDRA Provides Update Following In-person Meeting with FDA

May 14, 2024, 4:05 PM EDT - 2 years ago

ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update

May 7, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024

May 2, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents

Mar 28, 2024, 4:05 PM EDT - 2 years ago

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 21, 2024, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024

Feb 27, 2024, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Installs First TAEUS System in the UK

Feb 21, 2024, 8:00 AM EST - 2 years ago

New ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences' TAEUS System

Feb 14, 2024, 8:30 AM EST - 2 years ago

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

Nov 29, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

Nov 27, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences to Participate in The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference

Nov 14, 2023, 4:05 PM EST - 2 years ago

ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 8:00 AM EST - 2 years ago

ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents

Nov 7, 2023, 4:05 PM EST - 2 years ago

ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023

Nov 6, 2023, 8:00 AM EST - 2 years ago

ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD's The Liver Meeting® 2023

Sep 7, 2023, 8:00 AM EDT - 2 years ago

Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023

Aug 30, 2023, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA

Aug 23, 2023, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents

Aug 14, 2023, 4:05 PM EDT - 2 years ago

ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update

Aug 14, 2023, 1:30 PM EDT - 2 years ago

ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA

Aug 1, 2023, 8:00 AM EDT - 2 years ago

ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023

Jul 6, 2023, 4:45 PM EDT - 2 years ago

ENDRA Life Sciences Announces Adjournment of 2023 Annual Meeting of Stockholders to July 25, 2023

Jun 7, 2023, 8:00 AM EDT - 3 years ago

Study Highlighting ENDRA Life Sciences' TAEUS Technology to be Presented at EASL International Liver Congress 2023

May 15, 2023, 4:05 PM EDT - 3 years ago

ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update

topstockalerts Mar. 20 at 6:01 PM

$NDRA tends to move with catalyst flow, not constant action but can trend when it gets going.

0 · Reply

BlazingStocks Mar. 20 at 5:38 PM

0 · Reply

BlazingStocks Mar. 20 at 3:35 PM

0 · Reply

BlazingStocks Mar. 19 at 7:41 PM

0 · Reply

NewsAndFilings Mar. 19 at 7:04 PM

0 · Reply

BlazingStocks Mar. 19 at 2:35 PM

0 · Reply

BlazingStocks Mar. 18 at 7:25 PM

0 · Reply

SmallCapGrowth Mar. 18 at 4:29 PM

0 · Reply

BlazingStocks Mar. 18 at 3:14 PM

0 · Reply

BlazingStocks Mar. 17 at 7:13 PM

0 · Reply

Stockprofiler Mar. 17 at 5:46 PM

$NDRA on High Alert -ENDRA Life Sciences (NASDAQ: NDRA) is advancing its TAEUS® liver device to detect liver fat, targeting a 250-subject clinical trial for FDA De Novo submission by year-end 2025. The company reported Q2 2025 results with reduced operating expenses. Recent studies indicate high-level consistency, showing MRI-level results in assessing metabolic liver fat. https://pbs.twimg.com/media/HDoVtCjWsAAxjQh?format=png&name=900x900[/img] https://seekingalpha.com/pr/20415181-endra-s-taeus-liver-device-demonstrates-high-level-consistency-in-clinical-study-delivering via @SeekingAlpha @Nasdaq

0 · Reply

BlazingStocks Mar. 17 at 2:45 PM

0 · Reply

BlazingStocks Mar. 16 at 7:44 PM

0 · Reply

SmallCapGrowth Mar. 16 at 4:32 PM

🚨 $NDRA BIOTECH IMAGING ALERT – TAEUS LIVER DEVICE HITS MRI-LEVEL PRECISION IN STUDY! 🔥 https://www.tiktok.com/@stocksonhighalert713/video/7615226610253384981 @frontpagestocks

0 · Reply

BlazingStocks Mar. 16 at 3:43 PM

0 · Reply

PrnceMichael Mar. 16 at 3:06 PM

$NDRA ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care https://finance.yahoo.com/news/endra-taeus-liver-device-demonstrates-130000684.html

0 · Reply

BlazingStocks Mar. 13 at 5:28 PM

0 · Reply

BlazingStocks Mar. 13 at 2:55 PM

0 · Reply

SmallCapGrowth Mar. 13 at 1:22 PM

🚨 $NDRA BIOTECH IMAGING ALERT – TAEUS LIVER DEVICE HITS MRI-LEVEL PRECISION IN STUDY! 🔥 https://www.tiktok.com/@stocksonhighalert713/video/7615226610253384981 @frontpagestocks

0 · Reply

BlazingStocks Mar. 12 at 7:42 PM

$NDRA - Lasix ONYU received FDA approval on October 7, 2025, for the treatment of edema (due to fluid overload) in adult patients with chronic heart failure. The product enables selected patients to receive treatment at home, as prescribed by a clinician, without the need for a healthcare professional to administer the drug. https://finance.yahoo.com/news/sq-innovations-lasix-onyu-now-133000030.html

0 · Reply

BlazingStocks Mar. 12 at 5:41 PM

0 · Reply

BlazingStocks Mar. 12 at 2:27 PM

0 · Reply

Market Cap	2.57M
Revenue (ttm)	0.00
Net Income (ttm)	-11.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	19,200
Avg Vol	126,192
Day's Range	N/A - N/A
Shares Out	753,000.00
Stochastic %K	68%
Beta	-0.08
Analysts	Sell
Price Target	$30.00